title: An experimental study on the antitumor effect of 131I-17-AAG in vitro and in vivo.
abstract: OBJECTIVE
  To observe the antitumor effect of (131)I-17-allylamino-17-demethoxygeldanamycin ((131)I-17-AAG) in vitro/in vivo and explore its antitumor mechanism with a view to its potential therapeutic application.
  
  
  METHODS
  (131)I-17-AAG was prepared by the reaction of 17-AAG with Na [(131)I] in the presence of hydrogen peroxide. The effects of (131)17-AAG on cell growth inhibition and cell cycle distribution in vitro were studied in BEL-7402 cells lines. Following BEL-7402 tumor implantation by subcutaneous xenografts into nude mice, the reagents were injected through the tail vein, and the tumor volume was measured and analyzed. At the end of the experiment, tumor specimens were processed for histopathological analysis. Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) was used to investigate apoptosis. The expression change of Akt2 was tested by Western-blot analysis.
  
  
  RESULTS
  Methyl-thiazolyl-tetrazolium assay showed inhibition rates of 27.7 +/- 5.3%, 57.3 +/- 4.3%, and 63.7 +/- 3.1%, in Na(131)I group, 17-AAG group, and (131)I-17-AAG group, respectively. The inhibition rate in the (131)I-17-AAG group differed significantly between N(a131)I group and 17-AAG group (F = 229.49, P < 0.001). Following 48 h of treatment with the drug in each group, flow cytometry analysis indicated that detected sub-G peaks (black) were 1.54 +/- 0.13%, 5.72 +/- 1.05%, 12.97 +/- 1.44%, and 20.65 +/- 1.36%, in dimethyl sulfoxide (DMSO) group, Na(131)I group, 17-AAG group, and (131)I-17-AAG group, respectively. Following infusion for 32 days, the tumor volumes in the (131)I-17-AAG group were significantly smaller than those in the DMSO group (F = 24.18, P < 0.001) or the (131)I group (F = 20.68, P < 0.001). Histopathological and TUNEL analyses showed that (131)I-17-AAG inhibited the proliferation of tumor cells and induced apoptosis. The expression of Akt2 in (131)I-17-AAG was significantly lower than that in the DMSO group or (131)I group.
  
  
  CONCLUSIONS
  (131)I-17-AAG can effectively inhibit the growth of BEL-7402 tumor cells in vitro and in vivo. (131)I-17-AAG is a promising agent for the treatment of BEL-7402 cell tumor.
authors.affiliation: Nuclear Medicine Technology Institution, School of Clinical Medicine, Southeast University, No. 87 Dingjia Qiao Road 210009 Nanjing, Jiangsu, China.
authors.forename: Tu
authors.initials: T
authors.lastname: Wenyong
authors.forename: Liu
authors.initials: L
authors.lastname: Lu
authors.forename: Chen
authors.initials: C
authors.lastname: Daozhen
authors.forename: Yin
authors.initials: Y
authors.lastname: Weidong
authors.forename: Huang
authors.initials: H
authors.lastname: Ying
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D017209:Apoptosis / Q000528:radiation effects*; D016227:Benzoquinones / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000473:pathology* / Q000532:radiotherapy*; D045744:Cell Line, Tumor; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D047029:Lactams, Macrocyclic / Q000627:therapeutic use*; D008297:Male; D051379:Mice; D008819:Mice, Nude; D019275:Radiopharmaceuticals / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D016227:Benzoquinones; D007457:Iodine Radioisotopes; D047029:Lactams, Macrocyclic; D019275:Radiopharmaceuticals; C112765:tanespimycin